🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Studying cancer drugs overseas enriches FDA’s understanding of these drugs & ensures that treatments are applicable across the U.S. population, says FDA’s OCE Dir. Pazdur. Read more fda.gov/international-….

Great question about #ASCOGuidelines in #mesothelioma : should #bevacizumab be offered for pts w mesothelioma age>75? —I think risks overweight benefits for many and we have better treatments today as opposed to when this cisplatin/pem/bev trial was published (MAPS trial (2016)

Fantastic work together with Alfredo Addeo MD Jill Feldman and my global colleagues. Now we have identified clinical and molecular poor prognostic factors, we just have to push forward to improve outcomes for those patients. MD Anderson Cancer Center Eric K. Singhi, MD OncoViews OncoDaily

So you have learnt how to critically appraise the literature… How you use those skills is important. The goal should not be to display one’s critical appraisal skills. This is not a contest. We can find flaws in every trial. If you did a trial, chances are when it’s published

v2025.1 ASCO Living Guideline for stage 4 NSCLC w/o driver mutation out now in Journal of Clinical Oncology. key updates: ✅commentary of ph3 NIPPON trial and HARMONI-2 trial ✅commentary of ph3 DUBLIN-3 trial consider downloading the ASCO Guidelines Podcast for a concise summary of this update!

Whatever you want to know about #EGFR-addicted lung cancer, from the very beginning to today, you’ll find it in this masterpiece. It’s been a real privilege to collaborate on this project. Maxime Borgeaud Timothée Olivier, MD Jair Bar Kaushal Parikh Jill Feldman Xiuning Le MD PhD Alfredo Addeo MD

Excellent summary slides from Nitin Jain on updates & future directions in chronic lymphocytic #leukemia #CLL #leusm OncoAlert ‼️Exciting combination therapies & time-limited therapies coming

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development #mmsm #bmtsm Sagar Lonial MD Blood Cancer Journal nature.com/articles/s4140…

Over 10% of American women of childbearing age take SSRIs, with about half continuing use during pregnancy. However, questions remain about efficacy during pregnancy and potential risks to mother and child. Join our expert roundtable THIS MONDAY, July 21 at 10 am for a

And it is on! The annual Mayo Oncology review in Minneapolis. First on the podium, Dan Childs from GU oncology at Mayo Rochester. A fantastic review of the management of prostate cancer. Mayo Clinic Comprehensive Cancer Center Mayo Clinic Hematology-Oncology Fellowship Mayo Clinic Med Ed

I am not aware of any better speakers on the topic of GI radiation oncology than Krishan Jethwa. Everything just becomes crystal clear. This is why you want to attend Mayo Clinic Comprehensive Cancer Center CME courses in heme/onc. Quality updates for practitioners. Mayo Clinic Hematology-Oncology Fellowship

#ALKSummit25 KOL panel: What’s the role of local consolidation therapy in ALK+ #lungcancer? Dr D. Ross Camidge shares his views: “It’s not necessarily for everyone. How far do we push it? Should we consolidate w chemotherapy? Lots of questions & variables.” #LCSM #StrongerTogether

It’s official! 🎉 Excited and honored to be joining the Stanford Medicine Stanford Cancer Institute Head & Neck Med Onc faculty 👩‍🏫 this fall. So much gratitude 🙏 to the many mentors who have supported me along the way A. Dimitrios Colevas MD Joel W. Neal, MD, PhD Millie Das MD Heather Wakelee Tyler Johnson

The major event which took place this week in the BioTech and Pharma sector was without a doubt the death of a third patient from Sarepta Therapeutics’s Gene Therapy. Here’s an excellent short summary by CNBC’s Angelica Peebles which explains what went wrong with $SRPT. Worth watching! $XBI

David Gandara reviews the pivotal role of liquid biopsy in making precision oncology a reality for our patients with lung cancer. #NOSCM25

Always love hearing Julia Rotow MD speak! Great to spend time with her in NOLA! BOOKMARK her updated slide! 🔖

At NOSCM, Julia Rotow MD presents provocative data supporting continuation of EGFR TKIs after progressive disease, so-called treatment beyond progression (TBP). I am increasingly a believer. Invariably there are residual sensitive clones which need to be controlled

Dramatic progress in myeloma over last 20 years. Small font but download and use. 19 new drug approvals in 20 years.

Approach to newly diagnosed myeloma has become streamlined. Bookmark.

Wonderful opportunity sharing #BestofASCO 2025 highlights in Multiple Myeloma. How to (and not to) apply recent trial data in clinical practice. Some great talks on Leukemia, Lymphoma. #MMSM #CART #ASCODirect #ASCO25 #MedTwitter #MedEd Total Health | Oncology 📖🔬 ASCO Memorial Sloan Kettering Cancer Center